Search

GW Primary Care - Cleveland Park
To contact this location call: 202-525-5287 The GW Immediate and Primary Care is located in the historic area of Cleveland Park, centrally located in the heart of Washington, DC. Regardless…
Nicole Peña Chappell, MD
Nicole Peña Chappell, MD, is a board-certified gynecologic oncologist with The GW Medical Faculty Associates and serves as the division director of gynecologic oncology at the GW Cancer Center. Dr. Chappell treats patients with a range of gynecologic cancers, including uterine, ovarian, cervical,…
Lisa E. Menke, AuD
Dr. Lisa E. Raho is a Doctor of Audiology at The GW Medical Faculty Associates within the division of Otolaryngology. She graduated from Providence College in 2013 with a Bachelor of Arts (B.A.) degree in Elementary and Special Education. Dr. Raho earned her Doctor of Audiology degree (Au.D.) from…
A Randomized Phase III Trial of Intravesical BCG veRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE)
The study hypothesis is that BCG naïve non-muscle invasive bladder cancer (NMIBC) patients treated with intravesical Gemcitabine + Docetaxel (GEMDOCE) will result in a non-inferior event-free survival (EFS) compared to standard treatment with intravesical BCG. The purpose of this study is to test…
Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland
This phase IIa trial investigates the biomarker (plasma levels of PSA) of low-dose apalutamide in patients with prostate cancer confined in the prostate gland before surgery. Testosterone can cause the growth of prostate cancer cells, and Apalutamide blocks the use of testosterone by the tumor…
A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients With BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) and High-Risk NMIBC Patients Who Are BCG Naïve or Received Incomplete BCG Treatment
Primary Outcome Measures: Phase 1: Nature, incidence, relatedness, and severity of all AEs and SAEs according to the CTCAE v5.0. [Time Frame: Approximately 2 years] The type, incidence, relatedness and severity of treatment emergent adverse events of EG-70 as assessed by NCI-CTCAE V5.0 will be…
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer)
Primary objective to compare overall survival in metastatic prostate cancer patients who are randomized to standard systemic therapy (SST) plus definitive treatment of the primary tumor versus standard systemic therapy alone.
Just 29 Years Old, He Never Thought He'd Be Fighting for His Life
On March 10, Francis Wilson was going about his day when he first noticed a slight cough. "It's just allergies," he thought. He was too young and healthy to be seriously impacted by COVID-19, he thought.
How to Maintain Emotional Wellness During a Pandemic
The COVID-19 pandemic has been disruptive and disorienting in ways that most people have never experienced in their lives. The lifestyle changes, uncertainty, and isolation of this moment are tremendously stressful, even if one is not physically dealing with illness.
Karen Fagan, MD
Karen A. Fagan, MD, serves as the Chair of the GW Department of Medicine. In this role, Fagan provides leadership to the department’s 12 divisions, 579 faculty members including 119 full-time faculty, internal medicine residency program, and 12 accredited fellowships.